

## Further Reading

FSRH Clinical Effectiveness Unit. *Contraception of women aged over 40 years*. 2010 Jul. Faculty of Sexual and Reproductive Healthcare. Available online at: <https://www.fsrh.org/documents/cec-ceu-guidance-womenover40-jul-2010/>

## Declaration

Dr Terri Foran was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

The author's competing interests statement can be viewed at [www.healthed.com.au/monographs](http://www.healthed.com.au/monographs).

## References

1. Medicare Australia Item 35643. Source: [www.medicareaustralia.gov.au/statistics/mbs\\_item.shtml](http://www.medicareaustralia.gov.au/statistics/mbs_item.shtml) (Denominator determined by ABS population estimates) Accessed September 2016
2. FSRH Clinical Effectiveness Unit. *Contraception of women aged over 40 years*. 2010 Jul. Faculty of Sexual and Reproductive Healthcare. Available online at: <https://www.fsrh.org/documents/cec-ceu-guidance-womenover40-jul-2010/>
3. Wallace RB, Sherman BM, Bean JA, Treloar AE, Schlabaugh L. *Probability of menopause with increasing duration of amenorrhea in middle-aged women*. *Am J Obstet Gynecol*. 1979 Dec; 135(8): 1021-1024
4. Sherman BM, Korenman SG. *Hormonal characteristics of the human menstrual cycle throughout reproductive life*. *J Clin Invest*. 1975 Apr; 55(4): 699-706. Available online at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC301805/pdf/jcinvest00168-0076.pdf>
5. Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA. *Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception*. *Cochrane Database Syst Rev*. 2014 Jul; (7): CD004695
6. MacGregor EA, Hackshaw A. *Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements*. *J Fam Plann Reprod Health Care*. 2002 Jan; 28(1): 27-31
7. Calhoun AH. *A novel specific prophylaxis for menstrual-associated migraine*. *South Med J*. 2004 Sep; 97(9): 819-822
8. FSRH Clinical Effectiveness Unit. *UK medical eligibility criteria for contraceptive use 2016. Section B- Progestogen-only contraception*. Faculty of Sexual and Reproductive Healthcare. 2016 Jul. Available online at: <https://www.fsrh.org/standards-and-guidance/external/ukmec-2016-digital-version/>
9. Luukkainen T, Toivonen J. *Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties*. *Contraception*. 1995 Nov; 52(5): 269-76

### **Competing interests statement:**

Dr Terri Foran was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. The advertiser does not necessarily endorse or support the views expressed in this article.

Over the past 5 years Dr Terri Foran has had financial relationships (educational development, conference presentation, member of advisory board/consultancy) with a number of pharmaceutical companies which manufacture products for contraception. These companies include Bayer, MSD, Pfizer and Teva.